February 16 - 3
2021.02.16 16:10:05
South Korea’s major pharmaceutical companies are racing for the No. 2 title in the development of a coronavirus cure following the country’s first commercially available therapy Rekirona developed by Celltrion Inc. to treat Covid-19 patients with moderate symptoms.
According to the Ministry of Food and Drug Safety on Monday, a total of 15 candidate Covid-19 treatments are being tested, with ChongKunDang (CKD), GC Pharma and Daewoong Pharmaceutical making the final leg to the finish line to deliver their cure version.
CKD and GC Pharma are among the most promising players as they already completed Phase 2 clinical trials. CKD is a bit ahead as it plans to file for marketing approval of Napabeltan with the ministry this month. CKD said the approval process will begin as soon as clinical trial data compiled in Russia arrives, and marketing authorization is expected next month.
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]
According to the Ministry of Food and Drug Safety on Monday, a total of 15 candidate Covid-19 treatments are being tested, with ChongKunDang (CKD), GC Pharma and Daewoong Pharmaceutical making the final leg to the finish line to deliver their cure version.
CKD and GC Pharma are among the most promising players as they already completed Phase 2 clinical trials. CKD is a bit ahead as it plans to file for marketing approval of Napabeltan with the ministry this month. CKD said the approval process will begin as soon as clinical trial data compiled in Russia arrives, and marketing authorization is expected next month.
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]
[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]
